111/283089

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP2004/013664

International Filing Date : December 1, 2004

Priority Date(s) Claimed : December 16, 2003

Applicant(s) (DO/EO/US) : Helmut FIEBIG et al.

Title: DNA SEQUENCE, AND RECOMBINANT PREPARATION OF GROUP 4 MAJOR ALLERGENS FROM CEREALS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

\boxtimes	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:				
		within three months of the filing date of a national application other than a CPA under § 1.53(d);			
	\boxtimes	within three months of the actual filing date of the national phase of a PCT application; OR			
		before the mailing of a first substantive office action (including after filing of an RCE).			
	Under specif	37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods fied in 37 C.F.R. § 1.97(b), but before the mailing date of:			
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and			

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing llowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	nation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a ı	notice of allowance under 37 C.F.R. § 1.311;
	AND:	is filed	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Staten	nents U	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
<u>Cited</u>	Materia	<u>ls</u>	
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	\boxtimes	=	s of materials listed but not attached were cited in an international search dated July 8, 2005.
		Not re	quired by 37 CFR § 1.98.
		Copies	s of the materials listed are attached (except for the foregoing).

Non-English	Language References
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
\boxtimes	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document
	A = document defining the general state of the art
	O = non-written disclosure P = intercalated document
	P = intercalated document T = document cited to understand the theory or principle underlying the
	invention E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
	D = cited in the application
	L = cited for another reason
	&= publication of member of same patent family
\boxtimes	Translation of other relevant information on foreign search report
	In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure of formula, "Beispele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example, "Zusammenfassung" means summary, and "Tabelle" means table, and "Tabellen" means tables "in der Anmeldung erwaehnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means break, "Abildung" means figure.
Other Infor	<u>mation</u>
Payment of	f Fees Due (If Any):
	check for \$ covering the fee identified above is attached.

Please charge to Deposit Account No. 13-3402 \$_____ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza l
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333

Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3178

Date: June 15, 2006

AJZ:aap

K:\Merck\3000 - 3999\3178\Information Disclosure Statement.doc

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449A/P	TO		Complete if Known		
				Application Number	Unafsimed/20200	
INFO	RMATION	N DIS	CLOSURE	Filing Date	June 15-2006 0 0 0 0 9	
STAT	TEMENT	BY AF	PPLICANT	First Named Inventor	Helmut FIEBG et al.	
				Group Art Unit	Unassigned	
	(use as many s	heets as	necessary)	Examiner Name	Unassigned	
Sheet	1	of	2	Attorney Docket Number	MERCK-3178	

	U.S. PATENT DOCUMENTS						
		U.S. Patent Docui	nent				
Examiner Initials *	Cite No. ¹	Number	Kind Code ² (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
	1	2005074464			April 7, 2005		
	-						
<u>.</u>							
			-				
		· · · · · · · · · · · · · · · · · · ·					

		Foreign Patent Document					Pages, Columns, Lines, Where	
Examiner Initials*	Cite No.¹	Office ³	Number⁴	Kind Code ⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Relevant Passages	L _e
	2	wo	2004000881		Merck Patent GmbH	December 31, 2003		
	3	wo	03025009		The University of Melbourne	March 27, 2003		Equv to cite
 								
-								

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

JAP20 Rec'd PCT/PTO 15 JUN 2006

Please type a plus sign (+) inside this box	\rightarrow	+
riease type a plus sign () misiae and box		

PTO/SB/08A (08-00)

╁

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449A/PTO **Application Number** Unassigned / INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT Helmut FIEBIG et al. First Named Inventor Unassignee **Group Art Unit** Unassigned (use as many sheets as necessary) **Examiner Name MERCK-3178** Attorney Docket Number 2 2 of Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	٦	STUMVOLL S ET AL: "PURIFICATION, STRUCTURAL AND IMMUNOLOGICAL CHACATERIAZTION OF A TIMOTHY GRASS (PHLEIUM PRATENSE) POLLEN ALLERGEN, PHL P 4, WITH CROSS-REACTIVE POTENTIAL" BIOLOGICAL CHEMISTRY, BD. 383, NOR. 9, SEPTEMBER 2002, XP002260346.	
	4	ASTWOOD J D ET AL: "CLONING AND EXPRESSION PATTERN OF HOR V 9, THE GROUP 9 POLLEN ISOALLERGEN FROM BARLEY" GENE: AN INTERNATIONAL JOURNAL OF GENESE AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, BD. 182, NR. 1-2 DECEMBER 5 1996, XP004071930	
	5	RIHS H P ET AL: "POLYMERASE CHAIN REACTION BASED CDNA CLONONG OF WHEAT PROFILIN: A POTENTIAL PLANT ALLERGEN" INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, BD. 105, JANURAY 1994, XP000604627	
	6	FAHLBUSCH B ET AL: "DETECTION AND QUANTIFICATION OF GROUP 4 ALLERGENS IN GRASS POLLEN EXTRACTS USING MONOCLONAL ANTIBODIES: CLINICAL AND EXPERIMENTAL ALLERGY, BLACKWELL SCIENTIFIC PUBLICATIONS, LONDON, GB, BD. 28, NR. 7, JULY 1998, XP002260345	
	7	DATABASE EMBL'ONLINE! 19. NOVEMBER 2004 XP002325590	
	8	DATABASE EMBL 19. NOVEMBER 2004, XP002325591.	
	9	DATABASE ENBL 19. NOVEMBER 2004, XP002332685.	
	10	DATABASE ENBL 19. NOVEMBER 2004, XP002332686.	
	11	DATABASE EMBL 19. NOVEMBER 2004, XP002332687.	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.